You are here:

vortioxetine (Brintellix)

Advice

following a full submission:

vortioxetine 5mg, 10mg, 20mg film-coated tablet (Brintellix®) is accepted for restricted use within NHS Scotland.

Indication under review: the treatment of major depressive episodes in adults.

SMC restriction: patients who have experienced an inadequate response (either due to lack of adequate efficacy and/or safety concerns/intolerability) to two or more previous antidepressants.

In two phase III, randomised, double-blind studies in adults with major depressive disorder, vortioxetine was non-inferior to two alternative antidepressants at reducing the Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to week 8.

Drug Details

Drug Name: vortioxetine (Brintellix)
SMC Drug ID: 1158/16
Manufacturer: Lundbeck Ltd
Indication: Treatment of major depressive episodes in adults.
BNF Category:
Sub Category: 4.3 Antidepressant drugs
Submission Type: Full submission
Status: Restricted
Date Advice Published: 11 July 2016

Back